Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resigratinib in Advanced Tumors with FGFR2/FGFR3 Alterations
NCT05242822Phase 1Terminated
- Sponsor
- Kinnate Biopharma Inc.
- Start
- Mar 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of Resigratinib in solid tumor, intrahepatic cholangiocarcinoma (ICC) and urothelial carcinoma (UC) (2 arms), sponsored by Kinnate Biopharma Inc. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Incidence of Adverse Events up to 18 months and 4 more. Started Mar 2022; status: terminated.
02
Drugs
Resigratinib
03
Conditions
solid tumorintrahepatic cholangiocarcinoma (ICC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05242822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242822.